Medeon Biodesign, Inc. (TPEX: 6499)

Medeon Biodesign Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	948.35	1,238	483.9	735.32	1,128	472.06
Short-Term Investments	651.61	862.1	1,025	1,608	1,058	1,328
Trading Asset Securities	41.58	41.93	37.87	6.48	-	-
Cash & Short-Term Investments	1,642	2,142	1,547	2,350	2,186	1,800
Cash Growth	-36.92%	38.44%	-34.16%	7.49%	21.44%	42.75%
Accounts Receivable	38.92	41.77	32.35	10.12	164.81	72.41
Other Receivables	7.38	8.37	26.65	5.12	5.5	9.83
Receivables	46.3	50.15	59.01	15.25	170.31	82.23
Inventory	18.75	10.77	10.06	-	45.48	33.58
Prepaid Expenses	23.23	24.89	21.42	24.68	17.75	31.27
Total Current Assets	1,730	2,228	1,638	2,390	2,420	1,947
Property, Plant & Equipment	350.31	321.82	340.24	44.52	666.03	317.69
Long-Term Investments	-	-	1,876	1,847	-	-
Goodwill	106.74	106.74	106.74	39.23	72.19	72.19
Other Intangible Assets	59.99	64.33	73.44	39.71	141.33	168.58
Long-Term Deferred Tax Assets	32.95	-	-	-	4.12	2.34
Other Long-Term Assets	19.62	26.46	5.59	4.58	10.93	8.76
Total Assets	2,299	2,747	4,040	4,364	3,314	2,517
Accounts Payable	18.06	5.36	3.94	0.05	28.26	25.72
Accrued Expenses	90.71	98.01	73.09	68.33	73.19	60.17
Current Portion of Leases	52.64	47.15	36.69	14.53	23.53	20.85
Current Income Taxes Payable	-	37.97	56.78	66.74	41.75	24.93
Current Unearned Revenue	6.14	3.11	0.86	0.65	11.13	17.65
Other Current Liabilities	20.21	30.16	27.17	10	19.73	21.38
Total Current Liabilities	187.76	221.76	198.51	160.3	197.59	170.7
Long-Term Debt	-	-	-	-	12.94	-
Long-Term Leases	140.96	139.59	162.22	15.71	456.3	97.48
Long-Term Deferred Tax Liabilities	13.33	14.31	15.74	-	-	-
Total Liabilities	342.05	375.65	376.48	176	666.83	268.18
Common Stock	922.45	922.45	878.4	732.34	665.03	664.95
Additional Paid-In Capital	1,339	1,341	1,344	1,349	1,933	1,674
Retained Earnings	-385.05	31.25	1,355	2,072	-525.91	-333.18
Treasury Stock	-5.25	-10.6	-10.6	-10.6	-20.48	-
Comprensive Income & Other	54.15	36.18	30.94	-12.49	-6.68	-1.5
Total Common Equity	1,926	2,320	3,597	4,130	2,045	2,004
Minority Interest	31.86	51.51	66.1	58.15	602.47	244.5
Shareholders' Equity	1,957	2,371	3,664	4,188	2,648	2,249
Total Liabilities & Equity	2,299	2,747	4,040	4,364	3,314	2,517
Total Debt	193.6	186.74	198.91	30.24	492.76	118.33
Net Cash (Debt)	1,448	1,955	1,348	2,320	1,693	1,682
Net Cash Growth	-39.51%	45.01%	-41.87%	36.98%	0.68%	33.37%
Net Cash Per Share	15.72	21.24	14.65	25.19	18.48	18.36
Filing Date Shares Outstanding	92.14	92.04	92.02	92.02	91.63	92.16
Total Common Shares Outstanding	92.14	92.04	92.02	92.02	91.63	92.16
Working Capital	1,542	2,006	1,439	2,230	2,222	1,777
Book Value Per Share	20.90	25.21	39.10	44.89	22.32	21.75
Tangible Book Value	1,759	2,149	3,417	4,051	1,832	1,763
Tangible Book Value Per Share	19.09	23.35	37.14	44.03	19.99	19.13
Machinery	179.94	178.49	168.97	46.34	239.52	218.9
Construction In Progress	12.22	-	-	-	-	-
Leasehold Improvements	71.99	46.22	45.6	6.43	74.41	74.28

Source: S&P Capital IQ. Standard template. Financial Sources.